During the quarter, the company reported a sharp fall in overall revenue (GAAP) compared with the prior year, dropping by 43%. This headline decline mostly reflected the loss of COVID-19–related sales, which fell to near zero as pandemic-driven demand ended. At the same time, revenue from risk assessment testing and molecular services, both of which the company has now exited, slowed to minimal levels. OraSure Technologies (OSUR), a diagnostics and sample collection device company, released its second quart ...